Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	53.08	53.99	35.63	66.89	130.1	122.16
Short-Term Investments	25.53	62.88	135.93	176.64	47.5	72.08
Cash & Short-Term Investments	78.6	116.87	171.56	243.52	177.61	194.24
Cash Growth	-37.92%	-31.88%	-29.55%	37.11%	-8.56%	343.70%
Other Receivables	2.05	0.99	0.58	0.4	0.11	0.1
Receivables	2.05	0.99	0.58	0.4	0.11	0.1
Inventory	-	-	-	0.1	0.2	0.08
Prepaid Expenses	0.69	0.6	0.86	0.81	1.11	1.51
Other Current Assets	3.79	3.79	5.32	1.79	1.31	2.73
Total Current Assets	85.13	122.25	178.31	246.62	180.33	198.66
Property, Plant & Equipment	0.1	0.24	0.34	0.5	0.27	0.04
Long-Term Investments	-	-	59.97	62.55	15.84	31.62
Other Intangible Assets	0	0.03	0.08	-	-	-
Other Long-Term Assets	0.32	0.31	0.3	0.45	0.15	0.01
Total Assets	85.57	122.83	238.99	310.13	196.59	230.33

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	6.06	0.55	5.65	1.38	1.64	1.09
Accrued Expenses	18.43	20.36	21.6	10.51	5.94	3.86
Current Portion of Long-Term Debt	20.4	8.77	-	-	-	-
Current Portion of Leases	0.04	0.15	0.13	0.87	0.11	-
Other Current Liabilities	0.16	0.18	0.23	0.21	0.13	0.2
Total Current Liabilities	45.09	30.01	27.61	12.97	7.81	5.15
Long-Term Debt	5.87	22.4	29.42	29.9	-	-
Long-Term Leases	-	-	0.15	0.28	-	-
Total Liabilities	50.96	52.4	57.18	43.15	7.81	5.15

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0	0
Additional Paid-In Capital	559.91	516.8	506.99	489.45	359.95	352.98
Retained Earnings	-525.29	-446.46	-325.13	-222.8	-170.43	-127.57
Comprehensive Income & Other	-0.03	0.08	-0.05	0.31	-0.75	-0.23
Total Common Equity	34.61	70.43	181.82	266.97	188.78	225.18
Shareholders' Equity	34.61	70.43	181.82	266.97	188.78	225.18
Total Liabilities & Equity	85.57	122.83	238.99	310.13	196.59	230.33

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	26.31	31.31	29.7	31.05	0.11	-
Net Cash (Debt)	52.29	85.55	201.82	275.03	193.34	225.86
Net Cash Growth	-50.30%	-57.61%	-26.62%	42.25%	-14.40%	415.92%
Net Cash Per Share	0.78	1.41	3.36	5.66	4.76	11.26
Filing Date Shares Outstanding	72.33	72.21	60.57	60.08	41.03	40.47
Total Common Shares Outstanding	72.33	60.58	60.09	57.91	41.03	40.47
Working Capital	40.05	92.25	150.7	233.64	172.52	193.51
Book Value Per Share	0.48	1.16	3.03	4.61	4.60	5.56
Tangible Book Value	34.61	70.4	181.74	266.97	188.78	225.18
Tangible Book Value Per Share	0.48	1.16	3.02	4.61	4.60	5.56

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Oct 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 29, 2026

Data Sources Report a data error